Capital Management, Llcra C... Net Worth

The estimated Net Worth of Capital Management, Llcra C... is at least $16.6 Million dollars as of 11 April 2019. Capital C owns over 389,862 units of scPharmaceuticals Inc stock worth over $16,592,196 and over the last 7 years Capital sold SCPH stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Capital C SCPH stock SEC Form 4 insiders trading

Capital has made over 2 trades of the scPharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 389,862 units of SCPH stock worth $1,052,627 on 11 April 2019.

The largest trade Capital's ever made was buying 4,545,455 units of scPharmaceuticals Inc stock on 11 December 2018 worth over $50,000,005. On average, Capital trades about 1,645,106 units every 40 days since 2017. As of 11 April 2019 Capital still owns at least 3,247,005 units of scPharmaceuticals Inc stock.

You can see the complete history of Capital C stock trades at the bottom of the page.

What's Capital C's mailing address?

Capital's mailing address filed with the SEC is 20 Park Plaza, Boston, MA 02116, USA.

Insiders trading at scPharmaceuticals Inc

Over the last 7 years, insiders at scPharmaceuticals Inc have traded over $5,999,254 worth of scPharmaceuticals Inc stock and bought 6,409,552 units worth $61,370,807 . The most active insiders traders include Capital Management, L.P.Ra ..., Jonathan Silverstein, and Advisors Llc Orbi Med Capit.... On average, scPharmaceuticals Inc executives and independent directors trade stock every 112 days with the average trade being worth of $1,808,281. The most recent stock trade was executed by Leonard D Schaeffer on 26 August 2024, trading 11,347 units of SCPH stock currently worth $29,275.

What does scPharmaceuticals Inc do?

scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.

Complete history of Capital C stock trades at Dicerna Pharmaceuticals Inc and scPharmaceuticals Inc

scPharmaceuticals Inc executives and stock owners

scPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Tucker,
  President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Director
• John H. Tucker,
  Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director
• Rachael Nokes,
  Senior Vice President - Finance, Principal Accounting Officer
• Rachael Nokes,
  Sr. VP of Fin. & Principal Accounting Officer
• Jack Khattar,
  Independent Chairman of the Board
• Frederick Hudson,
  Independent Director
• Mette Agger,
  Independent Director
• Klaus Veitinger,
  Independent Director
• Minnie Baylor-Henry,
  Independent Director
• Leonard Schaeffer,
  Independent Director
• Mason Freeman,
  Independent Director
• Katherine Taudvin,
  Director, Corporate Development, Investor Relations
• Sara Bonstein,
  Independent Director
• Michael D. Hassman,
  Sr. VP of Technical Operations
• Dr. John Mohr Pharm.D.,
  Sr. VP of Clinical Devel. & Medical Affairs
• Capital Management, Llcra C...,
  
• Invest A/S Lundbeckfond,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Dorothy Coleman,
  Director
• Jonathan Silverstein,
  Director
• Pharmaceutical Industries L...,
  
• Troy A. Ignelzi,
  Chief Financial Officer
• Abraham Ceesay,
  Chief Operating Officer
• Kush Parmar,
  Director
• Andrew J. Schwab,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Capital Management, L.P.Ra ...,
  
• Partners Iv, Llc5 Am Co Inv...,
  
• William Tober Abraham,